The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007

The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007

Bibliographic Details
Main Authors:	Van Cutsem, E, Dicat, M, Haustermans, K, Arber, N, Bosset, J, Cunningham, D, De Gramont, A, Diaz-Rubio, E, Ducreux, M, Goldberg, R, Glynne-Jones, R, Haller, D, Kang, Y, Kerr, D, Labianca, R, Minsky, B, Moore, M, Nordlinger, B, Rougier, P, Scheithauer, W, Schmoll, H, Sobrero, A, Tabernero, J, Tempero, M, Van de Velde, C
Format:	Journal article
Published:	2008

Similar Items

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
by: Verslype, C, et al.
Published: (2009)

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.
by: Van Cutsem, E, et al.
Published: (2011)

The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010
by: van Cutsem, E, et al.
Published: (2011)

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
by: Verslype, C, et al.
Published: (2007)

Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).
by: Van Cutsem, E, et al.
Published: (2002)

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
by: Schmoll, H, et al.
Published: (2012)

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
by: Van Cutsem, E, et al.
Published: (2016)

Final results of the PETACC-1 trial of bolus 5-FU/LV vs raltitrexed: An unsuccessful story?
by: Popov, I, et al.
Published: (2008)

New approaches for the treatment of colorectal cancer in the adjuvant setting
by: Kerr, D, et al.
Published: (2004)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
by: Taieb, J, et al.
Published: (2012)

Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors
by: Cascinu, S, et al.
Published: (2003)

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
by: Sargent, D, et al.
Published: (2007)

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty
by: Josep Tabernero, et al.
Published: (2019-06-01)

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
by: Sargent, D, et al.
Published: (2005)

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
by: Bonnetain, F, et al.
Published: (2017)

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
by: Sobrero, A, et al.
Published: (2019)

Initial results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015
by: Muirhead, R, et al.
Published: (2016)

Maximising clinical benefit with adequate patient management beyond the second line in mCRC
by: Guillem Argiles, et al.
Published: (2019-04-01)

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
by: Folprecht, G, et al.
Published: (2008)

Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort study
by: Philippe P. Bulens, et al.
Published: (2022-09-01)

Efficacy of intraportal infusion for colon cancer: a fair assessment?
by: Marsoni, S, et al.
Published: (1991)

Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
by: Michel Ducreux
Published: (2009-02-01)

Do NSAIDs Prevent Colorectal Cancer?
by: Nadir Arber
Published: (2000-01-01)

Stepwise multicenter introduction of intensity modulated radiation therapy for anal cancer in the United Kingdom: From consensus guidance to large-scale prospective audit, prior to future clinical trials
by: Gilbert, D, et al.
Published: (2016)

The effect of metformin and GANT61 combinations on the radiosensitivity of prostate cancer cells
by: Gonnissen, A, et al.
Published: (2017)

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
by: Popov, I, et al.
Published: (2008)

Toxicity, tolerability & compliance of concurrent capecitabine or 5-fluorouracil in the radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort
by: Jones, C, et al.
Published: (2018)

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database
by: Salem, M, et al.
Published: (2018)

Endometrial cancer - reduce to the minimum. A new paradigm for adjuvant treatments?
by: Scheithauer Heike R, et al.
Published: (2011-11-01)

A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
by: Glynne-Jones, R, et al.
Published: (2007)

A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
by: Sebag-Montefiore, D, et al.
Published: (2005)

Therapeutic strategy in unresectable metastatic colorectal cancer
by: Benoist Chibaudel, et al.
Published: (2012-03-01)

Preliminary phase IISOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (IRT) in patients (pts) with locally advanced rectal cancer (LARC).
by: Glynne-Jones, R, et al.
Published: (2004)

Proteomic analysis of Leishmania mexicana differentiation.
by: Nugent, P, et al.
Published: (2004)

Anti-cancer activities of pH- or heat-modified pectin
by: Lionel eLeclere, et al.
Published: (2013-10-01)

The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo
by: Gonnissen, A, et al.
Published: (2016)

Personalizing survival predictions in advanced colorectal cancer: The ARCAD nomogram project
by: Sjoquist, KM, et al.
Published: (2017)

Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).
by: Glynne-Jones, R, et al.
Published: (2005)

How do nurses “Think Family” and support parents diagnosed with cancer who have dependent children?
by: Anne Arber
Published: (2016-01-01)

Faecal and urinary incontinence after multimodality treatment of rectal cancer.
by: Marilyne M Lange, et al.
Published: (2008-10-01)